Rallybio (RLYB)
(Real Time Quote from BATS)
$1.59 USD
0.00 (0.00%)
Updated May 21, 2024 10:48 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Rallybio Corporation [RLYB]
Reports for Purchase
Showing records 21 - 31 ( 31 total )
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Rallying Along - All Programs On Track [2Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Chief Executive Transition Appears Likely to be Seamless; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
New Captain, Same Ship -- Succession Plan Unveiled As COO Uden To Become CEO
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Ahead of Upcoming Catalysts, RLYB212 Detailed Data Presented at ISTH
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Full RLYB212 Phase 1b FNAIT Results Continue to Impress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Full Phase 1b FNAIT Data in June; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Steady As She Goes --- RLYB Making Progress Into ISTH Update [
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Rising Above Rivals in Rare Disease; Initiating at Buy With $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Company: Rallybio Corporation
Industry: Medical - Biomedical and Genetics
Initiating at Outperform, $17 Target; Devastating The Devastating Diseases
Provider: Wedbush Securities Inc.
Analyst: CHICO L